Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 62135-503

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 62135-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Rabeprazole Sodium Fig 2)

A line graph displaying mean heartburn scores over study days from -14 to 28. It compares three groups: Placebo (n=68), Rabeprazole 10 mg (n=64), and Rabeprazole 20 mg (n=67). The vertical axis shows mean scores from 0 (None) to 4 (Very Severe). Scores decrease notably after day 0 for the Rabeprazole groups compared to Placebo.*

FDA Label Image

Image Description (Rabeprazole Sodium Fig 3)

A line graph showing mean heartburn scores over study days for three groups: placebo (n=68), Rabeprazole 10 mg (n=64), and Rabeprazole 20 mg (n=67). The x-axis represents study days from -14 to 28, and the y-axis shows mean scores from 0 (none) to 4 (very severe). Scores decline over time, particularly after day 0.*

FDA Label Image

Image Description (Rabeprazole Sodium Fig 4)

Line graph comparing mean heartburn scores over time for two groups: placebo (n=58) and Rabeprazole Sodium 20 mg (n=59). The x-axis represents study days from -14 to 28, and the y-axis represents mean heartburn score from 0 (none) to 4 (very severe). Scores decrease for both groups after day 0, with the Rabeprazole group showing a greater reduction over time.*

FDA Label Image

Image Description (Rabeprazole Sodium Fig 5)

A line graph comparing mean heartburn scores over 28 study days between a placebo group and a Rabeprazole Sodium 20 mg group. The vertical axis shows mean scores from 0 (none) to 4 (very severe), and the horizontal axis shows study days from -14 to 28. Both groups show decreasing scores after day 0, with the Rabeprazole group consistently having lower scores than placebo.*

FDA Label Image

Image Description (Rabeprazole Sodium Tablets Label)

Label for Rabeprazole Sodium Delayed-Release Tablets 20 mg by Chartwell RX, LLC. The label indicates a 30-tablet prescription pack, with storage and dispensing instructions, and features a white and blue design with barcode and manufacturing details.*

FDA Label Image

Image Description (Raberazole Sodium Structure)

Chemical structure of rabeprazole sodium shown as a molecular diagram with labels including a sulfinyl group, a pyridine ring, and other characteristic features.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.